Tags

Type your tag names separated by a space and hit enter

Sofosbuvir Inhibits Hepatitis E Virus Replication In Vitro and Results in an Additive Effect When Combined With Ribavirin.
Gastroenterology. 2016 Jan; 150(1):82-85.e4.G

Abstract

Infection with hepatitis E virus genotype 3 may result in chronic hepatitis in immunocompromised patients. Reduction of immunosuppression or treatment with ribavirin or pegylated interferon-α can result in viral clearance. However, safer and more effective treatment options are needed. Here, we show that sofosbuvir inhibits the replication of hepatitis E virus genotype 3 both in subgenomic replicon systems as well as a full-length infectious clone. Moreover, the combination of sofosbuvir and ribavirin results in an additive antiviral effect. Sofosbuvir may be considered as an add-on therapy to ribavirin for the treatment of chronic hepatitis E in immunocompromised patients.

Authors+Show Affiliations

Division of Gastroenterology and Hepatology, Centre Hospitalier Universitaire Vaudois, University of Lausanne, Lausanne, Switzerland; Laboratory of Virology and Infectious Disease, The Rockefeller University, New York, New York.Rega Institute for Medical Research, University of Leuven, Leuven, Belgium.Laboratory of Virology and Infectious Disease, The Rockefeller University, New York, New York.Laboratory of Virology and Infectious Disease, The Rockefeller University, New York, New York.Rega Institute for Medical Research, University of Leuven, Leuven, Belgium.Division of Gastroenterology and Hepatology, Centre Hospitalier Universitaire Vaudois, University of Lausanne, Lausanne, Switzerland. Electronic address: Darius.Moradpour@chuv.ch.Division of Gastroenterology and Hepatology, Centre Hospitalier Universitaire Vaudois, University of Lausanne, Lausanne, Switzerland. Electronic address: Jerome.Gouttenoire@chuv.ch.

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

26408347

Citation

Dao Thi, Viet Loan, et al. "Sofosbuvir Inhibits Hepatitis E Virus Replication in Vitro and Results in an Additive Effect when Combined With Ribavirin." Gastroenterology, vol. 150, no. 1, 2016, pp. 82-85.e4.
Dao Thi VL, Debing Y, Wu X, et al. Sofosbuvir Inhibits Hepatitis E Virus Replication In Vitro and Results in an Additive Effect When Combined With Ribavirin. Gastroenterology. 2016;150(1):82-85.e4.
Dao Thi, V. L., Debing, Y., Wu, X., Rice, C. M., Neyts, J., Moradpour, D., & Gouttenoire, J. (2016). Sofosbuvir Inhibits Hepatitis E Virus Replication In Vitro and Results in an Additive Effect When Combined With Ribavirin. Gastroenterology, 150(1), 82-e4. https://doi.org/10.1053/j.gastro.2015.09.011
Dao Thi VL, et al. Sofosbuvir Inhibits Hepatitis E Virus Replication in Vitro and Results in an Additive Effect when Combined With Ribavirin. Gastroenterology. 2016;150(1):82-85.e4. PubMed PMID: 26408347.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Sofosbuvir Inhibits Hepatitis E Virus Replication In Vitro and Results in an Additive Effect When Combined With Ribavirin. AU - Dao Thi,Viet Loan, AU - Debing,Yannick, AU - Wu,Xianfang, AU - Rice,Charles M, AU - Neyts,Johan, AU - Moradpour,Darius, AU - Gouttenoire,Jérôme, Y1 - 2015/09/25/ PY - 2015/04/02/received PY - 2015/09/05/revised PY - 2015/09/11/accepted PY - 2015/9/27/entrez PY - 2015/9/27/pubmed PY - 2016/5/3/medline KW - Antiviral KW - Chronic Hepatitis KW - Immunosuppression KW - Polymerase Inhibitor SP - 82 EP - 85.e4 JF - Gastroenterology JO - Gastroenterology VL - 150 IS - 1 N2 - Infection with hepatitis E virus genotype 3 may result in chronic hepatitis in immunocompromised patients. Reduction of immunosuppression or treatment with ribavirin or pegylated interferon-α can result in viral clearance. However, safer and more effective treatment options are needed. Here, we show that sofosbuvir inhibits the replication of hepatitis E virus genotype 3 both in subgenomic replicon systems as well as a full-length infectious clone. Moreover, the combination of sofosbuvir and ribavirin results in an additive antiviral effect. Sofosbuvir may be considered as an add-on therapy to ribavirin for the treatment of chronic hepatitis E in immunocompromised patients. SN - 1528-0012 UR - https://www.unboundmedicine.com/medline/citation/26408347/Sofosbuvir_Inhibits_Hepatitis_E_Virus_Replication_In_Vitro_and_Results_in_an_Additive_Effect_When_Combined_With_Ribavirin_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0016-5085(15)01355-4 DB - PRIME DP - Unbound Medicine ER -